ATAI Stock Overview
A clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Atai Life Sciences N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.57 |
52 Week High | US$2.85 |
52 Week Low | US$1.03 |
Beta | 0.92 |
1 Month Change | -23.41% |
3 Month Change | -21.89% |
1 Year Change | -13.74% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -91.93% |
Recent News & Updates
Recent updates
ATAI: Enormous Potential Upside But No Clarity Yet
May 27Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
Oct 12Atai Life Sciences: Decentralized Drug Discovery Platform
Oct 06ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
Aug 15We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Jul 07atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Jun 30Atai Life Sciences N.V.: A First Take
Jun 02Atai Life Sciences And The Future Of Psychedelics For Mental Health
May 27We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22Shareholder Returns
ATAI | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -2.5% | 0.02% | -0.6% |
1Y | -13.7% | 15.2% | 22.5% |
Return vs Industry: ATAI underperformed the US Pharmaceuticals industry which returned 15.2% over the past year.
Return vs Market: ATAI underperformed the US Market which returned 22.5% over the past year.
Price Volatility
ATAI volatility | |
---|---|
ATAI Average Weekly Movement | 13.3% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ATAI's share price has been volatile over the past 3 months.
Volatility Over Time: ATAI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 83 | Florian Brand | www.atai.life |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
Atai Life Sciences N.V. Fundamentals Summary
ATAI fundamental statistics | |
---|---|
Market cap | US$262.84m |
Earnings (TTM) | -US$33.80m |
Revenue (TTM) | US$277.00k |
948.9x
P/S Ratio-7.8x
P/E RatioIs ATAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ATAI income statement (TTM) | |
---|---|
Revenue | US$277.00k |
Cost of Revenue | US$0 |
Gross Profit | US$277.00k |
Other Expenses | US$34.08m |
Earnings | -US$33.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.20 |
Gross Margin | 100.00% |
Net Profit Margin | -12,202.89% |
Debt/Equity Ratio | 8.8% |
How did ATAI perform over the long term?
See historical performance and comparison